Table of Contents

• Market overview: low-volume consolidation


• Sector highlights: PCB, MLCC, diamonds and CRO strength


• Fundamentals behind the sector moves


• Institutional perspectives: when cyclical investment may return


• Key insights table


• Afterwards...

You might want to know

Will subdued trading volumes delay a market rebound, or are sector-specific catalysts enough to reignite investor interest?

Which industries are showing early signs of demand recovery that could drive broader market performance?

Main Topic

On September 14, the A-share market experienced a modest, low-volume pullback. Major indices closed mixed to slightly lower: the Shanghai Composite edged down about 0.07% to 3,885.33, the Shenzhen Component fell roughly 0.64% to 13,384.57, the ChiNext index dropped near 1.10% to 3,285.58, and the STAR Market 50 declined about 1.62%. Combined turnover on the Shanghai and Shenzhen exchanges totaled approximately RMB 1,629.2 billion, representing a reduction of roughly RMB 342.7 billion from the previous trading day. These metrics indicate a market in consolidation with reduced participation rather than a broad-based sell-off.

Within this low-volume environment, several thematic pockets advanced. Hardware segments linked to compute capability showed pockets of strength: printed circuit board (PCB) related names led the gains with multiple stocks hitting daily up-limit levels. Other hardware-related concepts such as multilayer ceramic capacitors (MLCC) and lab-grown diamonds also recorded notable strength. Separately, contract research organizations (CROs) and related biotech services saw active flows, with several mid-cap names showing large intraday moves.

From a supply–demand and fundamentals perspective, growth in AI server demand is a principal driver supporting PCB chain sentiment. Research from leading securities houses highlights that critical nodes in the PCB value chain — panel makers, copper-clad laminate (CCL) producers, and drilling tool manufacturers — posted year-on-year revenue increases for August, with sequential gains as well. This pattern implies the industry is not simply plateaued at a high level; rather, capacity additions and continued order inflows are sustaining a cyclical upswing for these suppliers.

This key insight significantly impacts the understanding of why hardware-related equities are outpacing the broader market despite low overall turnover: persistent order growth tied to AI infrastructure is translating into measurable revenue acceleration across multiple upstream suppliers, validating investor interest in those segments.

Analyst reports further suggest that, as companies move toward third-quarter results disclosure, sectors such as MLCC, CCL, and PCB drilling tools may experience a rebound driven by improving operational readouts. Additionally, newer technology directions — for example, co-packaged optics (CPO) and diamond-based thermal management solutions — are being highlighted as potential market hotspots as demand for higher-performance hardware grows.

On the biotech side, the CRO theme showed tangible market attention. Several CRO and contract service companies reached daily circuit limits, reflecting concentrated buying. Choice data indicated that among 31 primary industry groups tracked, the pharmaceuticals & biotechnology sector attracted notable net inflows, suggesting capital rotation or selective risk-on interest into healthcare-related service providers.

Positive clinical and conference outcomes appear to be supporting the sector. For example, Chinese new drugs in lung cancer research posted a record presence at a recent global conference, with large numbers of oral and small oral presentations selected. Such scientific milestones can boost investor confidence in domestic oncology pipelines and, by extension, demand for clinical development services.

Institutional commentary on the overall market environment converges on the view that A-shares are adopting a wait-and-see stance: volume-contracted, sideways trading continues while the market awaits fresh external or domestic catalysts. Several broker-dealer strategy teams emphasize that while some risk concerns are likely priced in, a broader improvement in market risk appetite will require a combination of reduced overseas pressure, clearer domestic policy expectations, and a meaningful, sustained expansion in trading volume.

One strategist noted that short-term dispersion and volatility may persist, but the return of cyclical, earnings-driven investment is plausible as macro uncertainties subside and fundamentals reclaim their pricing role. In this framework, sectors with demonstrable demand momentum and improving revenue visibility are natural candidates for renewed investor focus. Another view underscores that the AI hardware trend — particularly the mid and upstream segments — has repeatedly shown robust, verifiable demand signals, and temporary liquidity-driven sentiment swings are unlikely to overturn the longer-term industry uptrend.

Summing up, the market is characterized by low turnover and selective leadership. Hardware segments tied to AI infrastructure and specialized electronic components, together with certain biotech service providers, are emerging as the most credible sources of near-term outperformance. Yet, for a broad-market recovery in risk appetite, multiple conditions need to align: easing external macro pressure, clearer domestic policy signals, and a reaffirmation of expanding on-exchange turnover.

Key Insights Table

Afterwards...

Looking ahead, investors and policymakers should continue monitoring structural demand drivers and technological shifts that underlie current sector rotations. In the hardware domain, sustained investment in AI infrastructure — including chips, high-density PCBs, advanced interconnects, and novel thermal solutions — merits close attention as it materially affects supplier revenue visibility. Improved visibility into capacity ramp-up and order backlogs will help confirm whether recent gains are durable.

In life sciences, the interplay between scientific progress (e.g., clinical readouts and international conference recognition) and service demand for CROs suggests that technological and regulatory advances can catalyze capital allocation into the sector. Continuous improvements in trial efficiency, new modality development, and cross-border collaboration are important areas to watch.

Finally, from a market-structure perspective, a sustainable recovery in broad risk appetite will likely require a confluence of clearer macro signals, supportive domestic policy clarity, and a demonstrated upward trend in market participation. Investors should therefore balance sector-specific opportunities with attention to liquidity trends and macro developments that will determine whether selective rallies evolve into a broader market advance.